Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Convertible Debt (2022 - 2025)

ImmunityBio (IBRX) has disclosed Convertible Debt for 4 consecutive years, with $477.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Convertible Debt rose 3.29% to $477.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $477.1 million, a 3.29% increase, with the full-year FY2025 number at $477.1 million, up 3.29% from a year prior.
  • Convertible Debt was $477.1 million for Q4 2025 at ImmunityBio, down from $500.8 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $588.0 million in Q3 2024 to a low of $165.3 million in Q3 2023.
  • A 4-year average of $450.3 million and a median of $488.9 million in 2025 define the central range for Convertible Debt.
  • Biggest YoY gain for Convertible Debt was 255.73% in 2024; the steepest drop was 19.95% in 2024.
  • ImmunityBio's Convertible Debt stood at $241.3 million in 2022, then skyrocketed by 139.13% to $577.0 million in 2023, then dropped by 19.95% to $461.9 million in 2024, then rose by 3.29% to $477.1 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Convertible Debt are $477.1 million (Q4 2025), $500.8 million (Q3 2025), and $492.1 million (Q2 2025).